Xeris Biopharma Holdings (XERS) Depreciation & Amortization (CF) (2020 - 2026)
Xeris Biopharma Holdings' (XERS) quarterly Depreciation & Amortization (CF) came in at $337000.0 in Q1 2026, up 6.98% YoY from $315000.0 in Q1 2025, and up 0.6% on a QoQ basis from $335000.0 in Q4 2025.
Xeris Biopharma Holdings (XERS) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings (XERS) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $337000.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 6.98% year-over-year to $337000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (up 9.79% YoY) and the FY2025 annual result came in at $1.3 million, up 7.01% from the prior year.
- Depreciation & Amortization (CF) advanced to $337000.0 in Q1 2026, from $335000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $391000.0 in Q3 2023 to a low of $281000.0 in Q2 2024.
- A 5-year average of $339000.0 and a median of $337000.0 in 2026 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) fell 27.2% — and 2025, when it advanced 15.66%.
- Tracing XERS's Depreciation & Amortization (CF) over 5 years: stood at $366000.0 in 2022, then dropped by 5.46% to $346000.0 in 2023, then slipped by 9.54% to $313000.0 in 2024, then rose by 7.03% to $335000.0 in 2025, then increased by 0.6% to $337000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $337000.0 (Q1 2026), $335000.0 (Q4 2025), and $338000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.86 Bn | 42.90 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.19 Bn | 39.54 Bn | 2.15 Bn | 241.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.79 Bn | 1.05 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 28.57 Bn | 22.77 Bn | 5.10 Bn | 1.02 Bn |
| 5 | United Therapeutics | 22.15 Bn | 19.49 Bn | 683.80 Mn | 24.20 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 672.30 Mn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.71 Bn | 11.18 Bn | 798.00 Mn | 171.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Xeris Biopharma Holdings | 1.50 Bn | 1.38 Bn | 79.59 Mn | 323,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 323,000.00 |
| Jun 30, 2026 | 323,000.00 |
| Mar 31, 2026 | 337,000.00 |
| Mar 31, 2026 | 337,000.00 |
| Dec 31, 2025 | 335,000.00 |
| Dec 31, 2025 | 335,000.00 |
| Sep 30, 2025 | 338,000.00 |
| Sep 30, 2025 | 338,000.00 |
| Jun 30, 2025 | 325,000.00 |
| Jun 30, 2025 | 325,000.00 |
| Mar 31, 2025 | 315,000.00 |
| Mar 31, 2025 | 315,000.00 |
| Dec 31, 2024 | 313,000.00 |
| Dec 31, 2024 | 313,000.00 |
| Sep 30, 2024 | 307,000.00 |
| Sep 30, 2024 | 307,000.00 |
| Jun 30, 2024 | 281,000.00 |
| Jun 30, 2024 | 281,000.00 |
| Mar 31, 2024 | 326,000.00 |
| Mar 31, 2024 | 326,000.00 |